Last reviewed · How we verify
NM-002
At a glance
| Generic name | NM-002 |
|---|---|
| Sponsor | 9 Meters Biopharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Proof of Concept Study in Patients With Short Bowel Syndrome (PHASE1, PHASE2)
- Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM-002 CI brief — competitive landscape report
- NM-002 updates RSS · CI watch RSS
- 9 Meters Biopharma, Inc. portfolio CI